CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01905592
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:54.536888+00:00
Published At: 2020-08-27T00:00:00+00:00
Record Updated At: 2022-11-15
Results Posted At: 2020-08-27
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Neoplasms, Breast", "Carcinoma of Breast", "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "Ovarian Neoplasms"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-11-15"
protocolSection.identificationModule.nctId: "NCT01905592"
protocolSection.identificationModule.officialTitle: "A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician\u0027s Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2020-08-27"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.